Helicobactor pylori: Basic Mechanisms to Clinical Cure 2002

Front Matter....Pages i-xxii
Front Matter....Pages 1-1
What are the new helicobacters?....Pages 3-13
 Helicobacter hepaticus and Helicobacter bilis : proinflammatory modulators of enterohepatic disease....Pages 15-29
Epidemiology and postulated pathogenesis of liver and biliary tract pathogenic Helicobacter species....Pages 31-41
Evidence implicating Helicobacter spp. in the pathogenesis of inflammatory bowel disease....Pages 43-51
Front Matter....Pages 53-53
The hierarchy of markers of virulence and disease causation — useful or disappointing?....Pages 55-63
SHP-2 tyrosine phosphatase and the Helicobacter pylori virulence factor CagA....Pages 65-71
What is the exact role of Lewis antigens and autoantibodies in Helicobacter pylori -related disease....Pages 73-81
Putative role of Helicobacter antigen in functional dyspepsia: a conceptual model....Pages 83-88
Acid adaptation of Helicobacter pylori ....Pages 89-100
Co-migration of Helicobacter pylori and humans: the evolving story....Pages 101-112
Front Matter....Pages 113-113
Progress in our understanding of H. pylori infection and gastritis....Pages 115-126
The role of pepsinogen assays as surrogate markers of gastritis dynamics in population studies....Pages 127-132
Multifocal Atrophic Gastritis (MAG) does not exist: new finding based on sectioning the entire stomach....Pages 133-142
Multifocal Atrophic Gastritis (MAG) is real, and important....Pages 143-148
Are there reliable non-invasive approaches to assessing gastritis for epidemiologic studies?....Pages 149-160
Animal models of gastritis: Helicobacter pylori and high-salt diet in the gerbil....Pages 161-167
Front Matter....Pages 169-169
The evolving epidemiology of Helicobacter pylori infection and gastric cancer....Pages 171-176
Virulence of Helicobacter pylori infection and gastric cancer: lessons from mouse models....Pages 177-183
The role of bacterial overgrowth in the stomach as an additional risk factor for gastritis....Pages 185-194
Role of ascorbate in gastric juice and the impact of Helicobacter infection....Pages 195-203
Front Matter....Pages 169-169
Mechanisms of injury: the effects of Helicobacter pylori on cell cycle control....Pages 205-214
Role of interleukin-1 beta and other potential genetic markers as indicators of gastric cancer risk....Pages 215-223
Results of intervention trials in Helicobacter pylori -infected populations....Pages 225-230
Which lessons can be drawn from the study of Helicobacter pylori related MALT lymphoma?....Pages 231-239
Front Matter....Pages 241-241
 Helicobacter pylori eradication leads to gastro-oesophageal reflux disease....Pages 243-252
 Helicobacter pylori eradication does not lead to gastro-oesophageal reflux disease....Pages 253-263
 Helicobacter pylori eradication in non-ulcer dyspepsia: the case for....Pages 265-274
 Helicobacter pylori eradication does not benefit non-ulcer dyspepsia....Pages 275-281
 Helicobacter pylori and dyspepsia strategies — debate: Yes — a test-and-treat strategy is a viable option in primary care....Pages 283-295
A ‘test-and-treat’ strategy is obsolete in primary care....Pages 297-300
 Helicobacter pylori should be eradicated in patients receiving long-term acid suppression....Pages 301-310
 Helicobacter pylori eradication is not necessary before long-term proton pump inhibitor treatment....Pages 311-317
 Helicobacter pylori and non-steroidal anti-inflammatory drugs: the debate is over....Pages 319-326
Front Matter....Pages 327-327
What are the global response rates to Helicobacter pylori eradication therapy?....Pages 329-338
What is the Helicobacter pylori global reinfection rate?....Pages 339-345
Is it time for quadruple therapy to be first line?....Pages 347-351
Eradication therapy should be different for dyspeptic patients compared with ulcer patients....Pages 353-361
 Helicobacter pylori resistance to antibiotics: prevalence, mechanism, detection. What’s new?....Pages 363-371
Antibiotic sensitivities of Helicobacter pylori vary at different gastric mucosal sites....Pages 373-381
Can the response to eradication therapy in Helicobacter pylori infection be predicted?....Pages 383-389
Front Matter....Pages 327-327
What constitutes failure of H. pylori eradication therapy?....Pages 391-400
How can the current strategies for eradication therapy be improved?....Pages 401-411
Novel targets for Helicobacter pylori eradication....Pages 413-422
 Helicobacter pylori management: how to improve the therapeutic confusion in practice....Pages 423-431
Ethical issues in the management of Helicobacter pylori infection....Pages 433-437
Are there geographic/regional differences in Helicobacter pylori eradication?....Pages 439-443
Front Matter....Pages 445-445
Management of Helicobacter pylori infection — a review of the available regional and national guidelines....Pages 447-462
Asia Pacific guidelines for the management of Helicobacter pylori infection....Pages 463-469
What is the impact of regional guidelines? China....Pages 471-474
 H. pylori infection: Clinical management from a European perspective....Pages 475-480
What is the impact of the regional guidelines? South America....Pages 481-485
Guidelines for management of Helicobacter pylori infection in the Middle East....Pages 487-488
Global consensus update for managing Helicobacter pylori infection: critical issues from the United States....Pages 489-496
Guidelines in the management of Helicobacter pylori infection in Japan....Pages 497-502
A proposal for future Helicobacter pylori eradication guidelines....Pages 503-512
Front Matter....Pages 513-513
Priorities for future research: microbiology....Pages 515-522
Priorities for further research in Helicobacter pylori management — the way forward....Pages 523-526
Back Matter....Pages 527-538